Others

Biohaven presents positive data on rhymepant, an oral CGRP receptor antagonist, with 16 presentations at the annual American Headache Society (AHS) scientific meeting in 2019 demonstrating the effectiveness of several types of patients and long-term security

[ad_1] NEW HAVEN, Conn., July 11, 2019 / PRNewswire / – Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the presentation of 16 scientific presentations (oral and poster) highlighting new data …

Read More »